Athersys, Inc presented data (5/14/10) supporting its MultiStem(R) programs. The findings were described in a series of presentations by leading researchers, clinicians and collaborators at their annual Investor Research & Development Day held in NYC, NY. Read more…
Opexa reported a Q1/10 loss of $1.422 M, or ($0.09) per share. OPXA is developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS). OPXA reported no revenues in Q1/10. Read more…
Scimitar Equity, LLC has issued a review of Aastrom Biosciences, Inc. (NASDAQ:ASTM) entitled, “Three (3) Late Stage Trials Focus the Future Stock Appreciation”. Scimitar Equity maintains a BUY ranking. This review is available at website: ASTM Q3/10 Review Read more…
Mesoblast is acquiring the outstanding shares of Angioblast Systems, a developer of mesenchymal precursor cells to position its marketing operation in 2012. The acquisition valued Angioblast at $222 M and gives Mesoblast a value of $405 M. Referencing our previous post, 5/10/10. Read more…
The Financial Industry Regulatory Authority (FINRA) recently issued guidance for FINRA registered firms about their obligations regarding customer suitability, disclosures, and other requirements for selling private placements. Read more…
ViaCyte, Inc is the new name for Novocell, a preclinical stage stem cell company. ViaCyte is a preclinical therapeutic company focused on diabetes based on pancreatic beta cell progenitors (Pro-Islet™) derived from human pluripotent stem cells. Read more…
BTIM has received $8 M from 2 investors. The purpose of the discount offer is to accelerate the raising of additional capital, without significant dilution of the ownership interests of existing BTIM security holders, by providing warrant holders with an incentive to exercise their warrants prior to the 10/31/10 warrant expiration date. BTIM intends to use the capital raised through the warrant exercises to strengthen its working capital reserves and for the expansion of its stem cell product development projects. Read more…
TiGenix (TiG) is a private biomedical company focused on innovative local treatments for damaged and osteoarthritic joints. TiG has established a portfolio of products which address specific musculoskeletal problems in relation to the biology of cartilage, bone and other connective tissues. Read more…
Stem cell researchers exploring a new approach for the care of respiratory diseases report that an experimental treatment involving transplantable lung cells was associated with improved outcomes in tests (on mice) with acute lung injury. The lung cells were derived from human embryonic stem cells. Read more…
Mesoblast’s (MSB) 1st trial has completed enrolment and been reviewed by the Data Safety and Monitoring Board evaluating its proprietary allogeneic, or “off-the-shelf”, stem cells for poster lateral lumbar spinal fusion at NY’s Hospital for Special Surgery. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.